Technology evaluation: LErafAON, NeoPharm.
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
Moreira
João Nuno
JN
Laboratory of Pharmaceutical Technology, Faculty of Pharmacy and Center for Neurosciences and Cell Biology, University of Coimbra, Rua do Norte, Coimbra 3000-295, Portugal. jmoreira@ci.uc.pt
Simões
Sérgio
S
D000818:Animals; D000970:Antineoplastic Agents / Q000378:metabolism / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008081:Liposomes / Q000378:metabolism*; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D009838:Oligodeoxyribonucleotides / Q000009:adverse effects / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020319:Oligodeoxyribonucleotides, Antisense / Q000009:adverse effects / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*; D019908:Proto-Oncogene Proteins c-raf / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use*
D000970:Antineoplastic Agents; C483019:LErafAON; D008081:Liposomes; D009838:Oligodeoxyribonucleotides; D020319:Oligodeoxyribonucleotides, Antisense; D019908:Proto-Oncogene Proteins c-raf